Washington University Institute of Clinical and Translational Sciences

华盛顿大学临床与转化科学研究所

基本信息

  • 批准号:
    10598597
  • 负责人:
  • 金额:
    $ 1017.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-06-19 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Contact PD/PI: Powderly, William G. Overall Component, 7. Project Summary/Abstract: The Institute of Clinical and Translational Sciences aligns with the CTSA goals of developing innovative solutions to improve the efficiency, quality, and impact of translational science. We will pursue five aims: Aim 1: Advance interdisciplinary programs to develop, promote, mentor, and retain highly qualified and diverse faculty, trainees, and staff who translate scientific discoveries into action, thereby becoming agents for change in their institutions and communities. We will enhance our existing research education and training programs, expand and diversify our workforce, and promote team science approaches to conduct and translate high-impact research that has the potential for changing the health of our community. (Translational Workforce Development). Aim 2: Facilitate research designed for implementation by engaging diverse communities and stakeholders in multidisciplinary collaborative teams at all stages of the translational research process, thereby demonstrating the benefit and impact of translational science. We will improve community health by collaborating with patient advocates, developing new partnerships, advancing the science of collaboration, and capitalizing on strengths in implementation science (Collaboration and Engagement). Aim 3: Integrate research across individual lifespans and apply translational science in complex and diverse populations to improve individual and community health through meaningful research collaborations and sustainable partnerships. We will address health disparities across the lifespan and among special populations, identify challenges that differentially affect urban and rural populations, catalyze the formation of transdisciplinary teams, and evaluate the outcomes of our work (Integration). Aim 4: Drive innovation, quality, efficiency, and inclusion in translational research to enhance collaborations and catalyze the implementation of discovery science. We will solve key logistical roadblocks in translational science and implement innovative methods to engage stakeholders and research participants, thereby targeting different populations, life stages, and health states (Methods and Processes). Aim 5: Apply innovative informatics and biostatistics solutions to improve quality and efficiency at every stage of translational research, and create an ecosystem that integrates diverse data and facilitates the interoperability, use, and reuse of digital assets. We will ensure the interoperability of current and archived data sets, implement new informatics technologies to enhance investigator productivity, and promote the formation of interdisciplinary research teams (Informatics). Impact. Successful completion of these five aims will transform translational research, accelerate the dissemination of new innovations across our entire population, and strengthen and diversify our workforce. Project Summary/Abstract Page 235 Contact PD/PI: Powderly, William G. Overall Component 8.
联系 PD/PI:Powderly, William G. 总体组成部分,7.项目摘要/摘要: 临床和转化科学研究所与 CTSA 开发创新的目标保持一致 提高转化科学的效率、质量和影响力的解决方案。我们将追求五个目标: 目标 1:推进跨学科项目,以开发、促进、指导和留住高素质人才 以及将科学发现转化为行动的多元化教师、学员和工作人员,从而 成为其机构和社区变革的推动者。我们将加强现有的研究 教育和培训计划,扩大我们的员工队伍并使其多样化,并推广团队科学方法 进行和转化有可能改变我们社区健康的高影响力研究。 (转化劳动力发展)。 目标 2:通过让不同社区和社区参与来促进旨在实施的研究 转化研究各个阶段的多学科协作团队的利益相关者 过程,从而展示转化科学的好处和影响。我们会改进 通过与患者倡导者合作、发展新的伙伴关系、推进科学发展来促进社区健康 协作,并利用实施科学的优势(协作和参与)。 目标 3:整合跨个体生命周期的研究,并将转化科学应用于复杂和复杂的领域 通过有意义的研究来改善不同人群的个人和社区健康 合作和可持续的伙伴关系。我们将解决整个生命周期的健康差异 在特殊人群中,确定对城市和农村人口有不同影响的挑战,促进 组建跨学科团队,并评估我们的工作成果(整合)。 目标 4:推动转化研究的创新、质量、效率和包容性,以增强 合作并促进发现科学的实施。我们将解决关键的物流问题 转化科学的障碍并实施创新方法来吸引利益相关者和研究 参与者,从而针对不同的人群、生命阶段和健康状况(方法和过程)。 目标 5:应用创新的信息学和生物统计解决方案来提高质量和效率 转化研究的每个阶段,创建一个整合多样化数据和知识的生态系统 促进数字资产的互操作性、使用和重用。我们将确保互操作性 当前和存档的数据集,实施新的信息技术以提高调查人员的生产力, 促进跨学科研究团队(信息学)的形成。 影响。成功完成这五个目标将改变转化研究,加速 在我们全体人口中传播新的创新,并加强我们的劳动力队伍并使之多样化。 项目总结/摘要第 235 页 联系 PD/PI:Powderly, William G. 整体组成 8.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William G. Powderly其他文献

Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031.
三甲曲沙联合甲酰四氢叶酸与甲氧苄氨嘧啶-磺胺甲恶唑治疗艾滋病患者中度至重度卡氏肺孢子虫肺炎发作:艾滋病临床试验组方案 029/031 的一项前瞻性、对照多中心研究。
  • DOI:
    10.1093/infdis/170.1.165
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fred R. Sattler;Peter T. Frame;R. Davis;Larry Nichols;Brent Shelton;B. Akil;Robert P. Baughman;C. Hughlett;Walter Weiss;C. Boylen;C. V. D. Horst;John H. Black;William G. Powderly;Roy T. Steigbigel;J. Leedom;Henry Masur;Judith Feinberg
  • 通讯作者:
    Judith Feinberg
Cyclic AMP Cyclic GMP VASCULAR tone isregulated by a variety of vasoactive mol cules : neurotransmitters
Cyclic AMP Cyclic GMP 血管张力受多种血管活性分子:神经递质调节
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. Tebas;A. Patick;E. Kane;Michael Klebert;Janet H. Simpson;Alejo Erice;William G. Powderly;Keith Henry
  • 通讯作者:
    Keith Henry
When to start antiretroviral therapy: asking the right question
何时开始抗逆转录病毒治疗:提出正确的问题
  • DOI:
    10.2217/fvl.11.26
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    William G. Powderly
  • 通讯作者:
    William G. Powderly
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
先前奈非那韦治疗失败的患者对含利托那韦-沙奎那韦疗法的病毒学反应。
  • DOI:
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. Tebas;A. Patick;E. Kane;Michael Klebert;Janet H. Simpson;Alejo Erice;William G. Powderly;Keith Henry
  • 通讯作者:
    Keith Henry
Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
接受明尼苏达抗淋巴细胞球蛋白 (MALG) 或 OKT3 预防排斥反应的肾移植受者出现症状性巨细胞病毒感染。
  • DOI:
  • 发表时间:
    1993
  • 期刊:
  • 影响因子:
    13.2
  • 作者:
    Thomas C. Bailey;William G. Powderly;Gregory A. Storch;Stephen B. Miller;John D. Dunkel;Robert S. Woodward;Edward Spitznagel;D. Hanto;W. Claiborne Dunagan
  • 通讯作者:
    W. Claiborne Dunagan

William G. Powderly的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William G. Powderly', 18)}}的其他基金

Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10827727
  • 财政年份:
    2023
  • 资助金额:
    $ 1017.84万
  • 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10700256
  • 财政年份:
    2022
  • 资助金额:
    $ 1017.84万
  • 项目类别:
WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES
华盛顿大学临床与转化科学研究所
  • 批准号:
    10321102
  • 财政年份:
    2017
  • 资助金额:
    $ 1017.84万
  • 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10556449
  • 财政年份:
    2017
  • 资助金额:
    $ 1017.84万
  • 项目类别:
Washington University Institute of Clinical Translational Sciences
华盛顿大学临床转化科学研究所
  • 批准号:
    9889200
  • 财政年份:
    2017
  • 资助金额:
    $ 1017.84万
  • 项目类别:
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES
吴氏临床与转化科学研究所
  • 批准号:
    10217859
  • 财政年份:
    2017
  • 资助金额:
    $ 1017.84万
  • 项目类别:
Rosiglitazone & Exercise Training: Effects on HIV-Infected People
罗格列酮
  • 批准号:
    6971952
  • 财政年份:
    2004
  • 资助金额:
    $ 1017.84万
  • 项目类别:
STUDY OF ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS
HIV 感染者每周一次阿仑膦酸钠的研究
  • 批准号:
    6971984
  • 财政年份:
    2004
  • 资助金额:
    $ 1017.84万
  • 项目类别:
WU 122: EVALUATE METABOLIC EFFECTS OF DISCONTINUATION OF ANTIRETROVIRAL THERAPY
WU 122:评估停止抗逆转录病毒治疗的代谢影响
  • 批准号:
    6971971
  • 财政年份:
    2004
  • 资助金额:
    $ 1017.84万
  • 项目类别:
CORE--CLINICAL FACILITY
核心——临床设施
  • 批准号:
    6649912
  • 财政年份:
    2002
  • 资助金额:
    $ 1017.84万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1017.84万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了